All In Biotech

Free tool

FAERS Monitor: Dificid

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 19, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 201699 or its brand name (Dificid, Fidaxomicin). Reports on generic versions are filed under their own applications.

Reports

2,417

Serious

1,442

60% of reports

Hospitalization

758

Death reported

258

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • clostridium difficile infection484
  • drug ineffective419
  • diarrhoea354
  • disease recurrence179
  • clostridium difficile colitis162
  • off label use135
  • nausea125
  • treatment failure120
  • abdominal pain88
  • no adverse event86
  • pyrexia78
  • vomiting73
  • death71
  • fatigue63
  • product dose omission issue56

Reports by year received

View as table
YearReports
201115
201236
2013276
2014122
2015162
2016121
201799
2018147
2019195
2020192
2021156
2022170
2023160
2024206
2025220
2026140

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,742 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
clostridium difficile infectionSignal484197.3182.092,339
clostridium difficile colitisSignal162135.0116.221,101
disease recurrenceSignal17932.928.55,489
treatment failureSignal12012.610.61,276
diarrhoeaSignal3544.84.31,085
no adverse eventSignal864.13.4203
abdominal painSignal883.32.7140
drug ineffectiveSignal4192.82.5502
pyrexia782.01.636
product dose omission issue561.71.314
nausea1251.41.213
vomiting731.41.16
off label use1351.31.112
death710.70.68
fatigue630.70.68

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.